References
- Toole JF, Chambless LE, Heiss G, Tyroler HA, Paton CC. Prevalence of stroke and transient ischemic attacks in the Atherosclerosis Risk in Communities (ARIC) study. Ann Epidemiol 1993;3:500–3
- Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: Framingham study. Ann Intern Med 1976;85:477–52
- Rosano GM, Vitale C, Fini M. Cardiovascular aspects of menopausal hormone replacement therapy. Climacteric 2009; 12(Suppl 1):41–6
- Hsia J, Langer RD, Manson JE, . Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch Intern Med 2006;166:357–65
- Lopes N, Vasudevans SS, Alvarez RJ, Binkley PF, Goldschmidt PJ. Pathophysiology of plaque instability: insights at the genomic level. Prog Cardiovasc Dis 2002;44:323–38
- Galis ZS, Khtzi JJ. Matrix metalloproteases in vascular remodeling and atherogenesis: the good, the bad and the ugly. Circ Res 2002;90:251–62
- Galis ZS, Sukhova GK, Lark MV, Libby P. Increased expression of matrix metalloproteases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493–503
- Kai H, Ikeda H, Yasukawa H, . Peripheral blood levels of matrix metalloprotease-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368–72
- Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloprotease-2 and -9 in rat brain after focal cerebral ischeamia. Neurobiol Dis 2001;8:834–46
- Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17Beta- oestradiol enhances release of matrix metalloprotease-2 from human vascular smooth cells. Biochim Biophys Acta 1998; 1406:169–74
- Lam KK, Cheng PY, Hsiao G, . Estrogen deficiency-induced alterations of vascular MMP-2, MT1-MMP, and TIMP-2 in ovariectomized rats. Am J Hypertens 2009;22:27–34
- Christodoulakos GE, Panoulis CP, Lambrinoudaki IV, . The effect of hormone therapy and raloxifene on serum matrix metalloprotease-2 and -9 in postmenopausal women. Menopause 2004;11:299–305
- Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloprotease and their inhibitor in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1948–9
- Kruegel J, Miosge N. Basement membrane components are key players in specialized extracellular matrices. Cell Mol Life Sci 2010;67:2879–95
- Zanger D, Yang BK, Ardans J, . Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797–802
- Natoli AK, Medley TL, Ahimastos AA, . Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloprotease expression. Hypertension 2005;46: 1129–34
- Marfella R, Di Filippo C, Portoghese M, Ferraraccio F. Proteasome activity as a target of hormone replacement therapy-dependent plaque stabilization in postmenopausal women. Hypertension 2008;51:1135–41
- Farach-Carson MC, Carson DD. Perlecan – a multifunctional extracellular proteoglycan scaffold. Glycobiology 2007;17:897–905
- Tannock LR, King VL. Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Rev Endocr Metab Disord 2008;9:289–300
- Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001;108:349–55